SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
This is a clear disclosure of shareholder voting results from Immuneering's Annual Meeting of Stockholders held on June 11, 2026, covering the election of two Class II directors (Peter Feinberg and Laurie B. Keating) and ratification of RSM US LLP as independent auditor. The filing explicitly states the vote tallies and outcomes for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →DoorDash held its annual meeting of stockholders on June 10, 2026. Shareholders voted on and approved three proposals: election of four Class III directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation, all with substantial majorities.
View raw filing on EDGAR →This Item 5.07 filing discloses the final results of the June 10, 2026 annual meeting of stockholders, including voting outcomes for three proposals: election of Class III directors (Aina E. Konold, Kristy Pipes, and Brian Ames), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure of shareholder vote results at an annual meeting is a core shareholder_vote_results event, and the outcomes are material to investors assessing board composition and governance.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the Company's Annual Meeting of Stockholders held on June 9, 2026. The filing reports the results of two proposals: (1) election of seven directors, with detailed vote tallies for each nominee, and (2) ratification of EY as independent auditor. This is a textbook Item 5.07 disclosure and is material as it reflects stockholder approval of board composition and auditor appointment.
View raw filing on EDGAR →American Airlines Group held its 2026 Annual Meeting on June 10, 2026, with shareholders voting on seven proposals including election of all 12 director nominees (passed with substantial majorities), ratification of KPMG as independent auditor, advisory approval of executive compensation, and several governance proposals.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from BRT Apartments Corp.'s annual meeting held on June 10, 2026. The filing presents detailed vote tallies for four proposals: election of directors (Carol Cicero, Frederic H. Gould, Gary Hurand, and Elie Weiss), advisory vote on executive compensation, ratification of Ernst & Young LLP as independent auditor, and approval of the 2026 Incentive Plan. All proposals were approved, making this a standard shareholder_vote_results disclosure under Item 5.07.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure presenting the final voting results from Ascent Industries' Annual Meeting of Shareholders held June 10, 2026. The filing reports tabulated votes for three proposals: election of seven directors, advisory approval of named executive officer compensation, and ratification of Baker Tilly US, LLP as independent auditor. All results are presented in standard vote-count format (For, Against, Abstain, Broker Non-Votes), which is the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →The filing discloses results of a shareholder vote at the Annual Meeting of Shareholders on June 10, 2026, where the Board of Directors was re-elected in its entirety. This is a classic shareholder_vote_results disclosure under Item 5.07, and board re-election is material to investors as it affects corporate governance and oversight.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Valaris Limited's 2026 Annual General Meeting held on June 10, 2026. The filing reports voting outcomes on three matters: election of six directors (Elizabeth D. Leykum, Anton Dibowitz, Dick Fagerstal, Joseph Goldschmid, Catherine J. Hughes, and Kristian Johansen), advisory approval of named executive officer compensation, and appointment of KPMG LLP as independent auditor. This is a quintessential Item 5.07 disclosure with detailed vote tallies (For, Against, Abstain, Non-Votes) for each proposal.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from FCX's 2026 annual meeting held on June 10, 2026. The filing reports final voting tallies for three proposals: election of eleven directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities, and the disclosure includes detailed vote counts (for, against, abstentions, and broker non-votes) for each director nominee and proposal, which is the standard format for shareholder meeting results disclosures.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Credit Acceptance's June 10, 2026 Annual Meeting of Shareholders. The filing reports voting outcomes on three proposals: election of six directors, advisory approval of named executive officer compensation, and ratification of Grant Thornton LLP as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non Votes) for each proposal are the core content of the filing, making this unambiguously a shareholder_vote_results event that is material to investors assessing board composition and governance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final voting results from Biogen's June 9, 2026 Annual Meeting of Stockholders. The filing presents detailed vote tallies for three matters: election of ten directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of executive compensation. These are routine but material shareholder governance matters that affect investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from TeraWulf's June 9, 2026 Annual Meeting of Stockholders, covering three proposals: election of nine directors, advisory vote on executive compensation, and ratification of Deloitte as independent auditor. The filing presents detailed vote tallies for each proposal, which is the core content of Item 5.07 disclosures and is material to investors assessing corporate governance and board composition.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Lulu's Fashion Lounge's Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for four proposals: election of two Class II directors (Anisa Kumar and Crystal Landsem), ratification of Deloitte & Touche LLP as auditor, approval of a certificate amendment reducing authorized shares, and approval of officer exculpation provisions. All proposals passed. Shareholder vote results are material to investors as they confirm governance outcomes and corporate actions approved by the shareholder base.
View raw filing on EDGAR →Voyager's stockholders approved the 2026 Annual Meeting matters, including election of three Class II directors (Geraghty, Hyman, Sandrock), an advisory vote on named executive officer compensation, ratification of Ernst & Young LLP as independent auditor, and an amendment to increase authorized shares from 125 million to 245 million total shares and from 120 million to 240 million common shares.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Grand Canyon Education's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes on four matters: election of six directors, approval of the 2026 Equity Incentive Plan, advisory approval of named executive officer compensation, and ratification of KPMG LLP as independent auditor. The detailed vote tallies (for, against, abstain, broker non-votes) for each proposal are the hallmark of Item 5.07 disclosures and constitute material information affecting investor understanding of corporate governance and shareholder sentiment.
View raw filing on EDGAR →Entrada Therapeutics held its Annual Meeting of stockholders on June 10, 2026, with shareholders voting on four proposals: election of two Class II directors (Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D.), ratification of Ernst & Young LLP as independent auditor, and approval of Amendment No. 1 to both the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan. All proposals passed with clear majorities.
View raw filing on EDGAR →Shareholders voted at the Annual Meeting to elect Ann M. Danner, William A. Lamkin, and Matthew P. Jordan to Class I of the Board for three-year terms, and ratified Deloitte & Touche LLP as the independent auditors for 2026, with specific vote tallies reported for each matter.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Virtu Financial's 2026 annual meeting held on June 10, 2026. The filing reports voting outcomes on three matters: election of Class II directors (Aaron Simons, Joseph J. Grano Jr., and Joanne M. Minieri), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three items passed with substantial majorities, making this a routine but material governance disclosure required under Item 5.07.
View raw filing on EDGAR →The Company's annual meeting of shareholders held on June 9, 2026 resulted in election of seven Trustees, approval of a non-binding advisory vote on named executive officer compensation, determination of frequency for future compensation advisory votes, and ratification of Deloitte & Touche LLP as independent auditors.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Clean Energy Fuels' 2026 annual meeting held on June 10, 2026. The filing reports voting outcomes on three proposals: election of six directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →Astrana Health held its Annual Meeting on June 10, 2026, with shareholders voting on four proposals: election of nine directors, ratification of Ernst & Young LLP as independent auditor, advisory approval of executive compensation, and approval of the amended 2024 equity incentive plan. The filing discloses detailed vote tallies for all proposals.
View raw filing on EDGAR →Argan Inc. held its 2026 Annual Meeting of Shareholders on June 10, 2026, with voting results on three matters: election of nine board members, non-binding say-on-pay approval, and ratification of Grant Thornton LLP as independent auditors.
View raw filing on EDGAR →Perpetua Resources held its 2026 Annual General Meeting of Shareholders on June 4, 2026, with all four proposals passing by substantial majorities: fixing the board at nine directors, electing nine directors (including Marcelo Kim, Christopher J. Robison, and Alexander Sternhell), approving the 2026 Equity Incentive Plan, and ratifying PricewaterhouseCoopers LLP as auditor.
View raw filing on EDGAR →Iovance held its Annual Meeting of Stockholders on June 10, 2026, with certified voting results on seven proposals including director elections, executive compensation advisory votes, auditor ratification, equity plan amendments, and a certificate of incorporation amendment to increase authorized shares. All proposals passed.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of McEwen Inc.'s annual shareholder meeting held June 4, 2026. The filing presents voting tallies for three proposals: (i) election of eleven directors, (ii) ratification of Ernst & Young LLP as independent auditor, and (iii) approval of common stock issuance to Robert R. McEwen. All three proposals passed with substantial majorities, making this a material governance event that investors rely on to assess board composition and auditor continuity.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on six proposals: election of five directors (Dr. Khalid Islam, Chris A. Rallis, Marco Brughera, Jodi Cook, Jeffrey Hackman), appointment of auditors (Haskell & White LLP), advisory votes on executive compensation and frequency thereof, amendments to the 2020 Equity Incentive Plan, and adoption of the 2026 Equity Inducement Plan. All proposals were approved by shareholders on June 10, 2026. This is material as it confirms governance and compensation decisions affecting the company's leadership and capital structure.
View raw filing on EDGAR →At the 2026 annual meeting of stockholders held on June 9, 2026, the Company's stockholders approved an amendment to the Amended and Restated 2010 Stock Incentive Plan to increase the aggregate number of authorized shares by 6,500,000 for employee compensation purposes.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Taboola's Annual General Meeting held on June 9, 2026. The filing reports voting outcomes on five proposals: director re-elections, advisory compensation vote, compensation policy approval, CEO compensation terms, and auditor re-appointment. All proposals passed by requisite majorities, making this a material governance event that affects investor understanding of shareholder approval and corporate oversight.
View raw filing on EDGAR →PCSC shareholders voted on June 10, 2026 to approve an amendment to the articles of association extending the deadline for completing an initial business combination from June 13, 2026 to June 13, 2027. The Extension Amendment Proposal passed with overwhelming support (8,515,798 for, 75 against, 4,866 abstain) at a quorum of 76.5% of voting power.
View raw filing on EDGAR →Shareholders voted at the June 9, 2026 annual meeting on three proposals: election of six directors, ratification of Whitley Penn as independent auditor, and an advisory vote on executive compensation. All three proposals passed with substantial majorities.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of a special stockholder meeting held on June 10, 2026, where Kennedy-Wilson shareholders voted on three proposals: (1) adoption of the Merger Agreement with Kona Bidco, LLC (approved with 148,957,598 votes for vs. 535,978 against), (2) advisory compensation approval (approved 139,504,118 for vs. 9,411,306 against), and (3) adjournment proposal (approved 143,306,344 for vs. 6,169,767 against). The merger proposal approval is material as it enables the anticipated June 16, 2026 closing of a change-of-control transaction.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of CME Group's 2026 Annual Meeting of Shareholders held on June 9, 2026 (reconvened from May 14 due to quorum issues). The filing details voting outcomes on five substantive proposals: elimination of Class B-1, B-2, and B-3 director election rights (Items 4–6); a certificate of incorporation amendment (Item 7); and election of Class B directors (Item 8). The disclosure includes vote tallies, percentages, and quorum determinations across multiple share classes, which is the core content of a shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 4, 2026 annual meeting of stockholders, covering three proposals: election of six directors, ratification of KPMG as independent auditors, and an advisory vote on executive compensation. The filing presents detailed vote tallies for each matter, which is the core content of Item 5.07 and constitutes a material event affecting corporate governance and board composition.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Strategy Inc's 2026 Annual Meeting of Stockholders held on June 8, 2026, including voting outcomes on five proposals: election of eight directors, ratification of KPMG LLP as independent auditor, advisory vote on named executive officer compensation, ratification of preferred stock certificate amendments, and approval of dividend payment frequency changes. The detailed vote tallies (For/Against/Abstain/Broker Non-votes) for each proposal are the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses preliminary results from Medallion Financial Corp.'s 2026 Annual Meeting of Stockholders via press release. This is a direct disclosure of shareholder voting outcomes, which is material to investors as it determines board composition, executive compensation approvals, and other governance matters. The event matches the shareholder_vote_results taxonomy entry.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from QNB Corp.'s June 9, 2026 Annual Meeting of Shareholders. The filing reports voting outcomes on three proposals: election of Class II directors (Bergman, Bimes, Brown, and Stauffer), approval of the 2026 Employee Stock Purchase Plan, and ratification of Baker Tilly US, LLP as independent auditor. All proposals passed with substantial majorities, making this a material governance event that investors rely on to confirm board composition and audit oversight.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for two proposals: election of Class II directors (H. Edward Fleming, Jr., M.D. and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.) and ratification of PricewaterhouseCoopers LLP as independent auditor. Both proposals passed with strong majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Solid Biosciences' Annual Meeting of Stockholders held on June 10, 2026, covering five matters: election of Class II directors (Clare Kahn, Adam Stone, Lynne Sullivan), ratification of Class I director Ilan Ganot, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of a Share Increase Amendment (doubling authorized common shares from 240M to 480M), and advisory approval of named executive officer compensation. The filing includes detailed vote tallies for each matter, confirming the core purpose of Item 5.07 shareholder vote result disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from enGene Therapeutics' 2026 Annual General Meeting held on June 9, 2026. The filing reports final voting tallies for Proposal 1 (Election of Directors) and Proposal 2 (Appointment and Remuneration of Auditor), with detailed vote counts for each director nominee and the auditor appointment. This is a quintessential Item 5.07 disclosure required by SEC rules and is material to investors as it confirms board composition and auditor selection.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Prelude Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratification of Ernst & Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on the frequency of compensation votes. All proposals were approved by stockholders, with detailed vote tallies provided for each nominee and proposal.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Rapport Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class II directors (James Healy, Robert J. Perez, and Raymond Sanchez) and (ii) ratification of PwC as the independent auditor. The detailed vote tallies (For/Withheld/Broker Non-Votes for directors; For/Against/Abstain for auditor ratification) are the core content of Item 5.07, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Amplitude's 2026 annual meeting of stockholders held on June 9, 2026. The filing presents voting results for three proposals: election of Class II directors (Pat Grady, Curtis Liu, Catherine Wong), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) are the core content of the disclosure.
View raw filing on EDGAR →Syndax Pharmaceuticals held its Annual Meeting of Stockholders on June 10, 2026, with shareholders voting on five proposals: election of directors (Legault and Metzger), advisory vote on executive compensation, ratification of auditors, and approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. All proposals passed.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from MarketAxess Holdings' 2026 Annual Meeting of Stockholders held on June 10, 2026, filed under Item 5.07. The filing reports voting outcomes for four proposals: election of 12 directors, ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation ("say-on-pay"), and a stockholder proposal regarding special meeting rights. All proposals passed with substantial majorities. This is material as it reflects shareholder approval of governance and compensation matters.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from Aimco's 2026 Annual Meeting of Stockholders held on June 10, 2026, covering three proposals: election of nine directors, ratification of Grant Thornton LLP as independent auditor, and advisory approval of executive compensation. The detailed tabulation of votes for and against each proposal is the core disclosure required under Item 5.07.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Maze Therapeutics' 2026 annual meeting held on June 8, 2026. The filing reports voting outcomes for two proposals: election of directors Jason Coloma and Neil Kumar (both elected), and ratification of Ernst & Young LLP as independent auditor (ratified with overwhelming support). The detailed vote tallies and quorum confirmation are hallmarks of shareholder_vote_results disclosures.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Exzeo Group's Annual Meeting of Shareholders held on June 9, 2026. The filing reports voting outcomes for two proposals: (1) election of two Class A directors (Paresh Patel and Irene Hurst) and (2) ratification of Forvis Mazars, LLP as independent auditor. The specific vote tallies (For, Against, Withheld, Abstained) are provided for each matter, which is the hallmark of Item 5.07 shareholder vote results disclosure.
View raw filing on EDGAR →Stockholders approved six proposals at the Annual Meeting on June 10, 2026, including election of directors, ratification of auditors, approval of a Series B convertible preferred stock issuance that triggers a change of control under Nasdaq rules, authorization of additional common shares, and approval of equity compensation plans.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Intellia's Annual Meeting held on June 9, 2026. The filing presents voting results for three proposals: election of three class I directors (Muna Bhanji, Brian Goff, and Jesse Goodman), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →